Managing Comorbidities in Advanced Renal Cell Carcinoma Treatment

In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in community practice and how these factors influence treatment selection. Dr. Wulff and Dr. Geynisman discuss practical strategies for adapting guideline-based therapies in patients with cardiovascular disease, pulmonary conditions, and baseline anemia. The panel emphasizes careful selection of systemic therapies based on safety profiles, noting that VEGFR TKIs may require close monitoring in patients with cardiovascular risk, while immunotherapy use may be limited in those with significant autoimmune or pulmonary concerns. They also address the impact of newer agents, such as HIF-2α inhibitors, which may exacerbate anemia or hypoxia, requiring additional consideration. Dose modifications, proactive toxicity management, and multidisciplinary care are highlighted as key components of optimizing outcomes. The discussion reinforces that effective management of advanced renal cell carcinoma requires thoughtful integration of comorbidities into treatment planning.